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ABSTRACT
Posaconazole prophylaxis has demonstrated efficacy in the prevention of invasive 
aspergillosis during prolonged neutropenia following acute myeloid leukemia induction 
chemotherapy. Antifungal treatment decreases serum galactomannan enzyme 
immunoassay diagnostic accuracy that could delay the diagnosis and treatment.
We retrospectively studied patients with acute myeloid leukemia who underwent 
intensive chemotherapy and antifungal prophylaxis by posaconazole oral suspension. 
Clinical, radiological, microbiological features and treatment response of patients with 
invasive aspergillosis that occurred despite posaconazole prophylaxis were analyzed. 
Diagnostic accuracy of serum galactomannan assay according to posaconazole plasma 
concentrations has been performed.
A total of 288 patients with acute myeloid leukemia, treated by induction 
chemotherapy, who received posaconazole prophylaxis for more than five days were 
included in the present study. The incidence of invasive aspergillosis was 8% with 12 
(4.2%), 8 (2.8%) and 3 (1%), possible, probable and proven invasive aspergillosis, 
respectively. Posaconazole plasma concentration was available for 258 patients. 
Median duration of posaconazole treatment was 17 days, and median posaconazole 
plasma concentration was 0.5 mg/L. None of patients with invasive aspergillosis and 
posaconazole concentration ≥ 0.5 mg/L had a serum galactomannan positive test. 
Sensitivity of serum galactomannan assay to detect probable and proven invasive 
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aspergillosis was 81.8%. Decreasing the cut-off value for serum galactomannan 
optical density index from 0.5 to 0.3 increased sensitivity to 90.9%.
In a homogenous cohort of acute myeloid leukemia patients during induction 
chemotherapy, increasing the posaconazole concentration decreases the sensitivity 
of serum galactomannan assay.
INTRODUCTION
Treatment of acute myeloid leukemia (AML) is 
generally divided in 2 steps: induction and consolidation. 
This treatment has not been really modified for 40 years 
and most of the prognostic improvement came from 
supportive care and allogeneic stem cell transplant [1]. 
The standard regimen of AML induction chemotherapy 
is a combination of an anthracycline with continuous 
infusion of cytarabine. This treatment leads to a deep 
and prolonged neutropenia which is a classical risk 
factor of invasive fungal disease (IFD), mainly invasive 
aspergillosis (IA).
Establishing early diagnosis of IA is a major issue 
hampered by poor clinical signs and the difficulty of 
mycological documentation. The diagnosis is based on 
a set of arguments: host factor, clinical and radiological 
patterns and mycological criteria for assignment of 
possible, probable and proven IA, according to European 
Organization for Research and Treatment of Cancer/
Mycoses Study Group (EORTC/MSG) criteria [2].
Direct microbiological diagnosis is rare in 
immunocompromised patients, requiring the use of 
indirect test such as serum Galactomannan (GM) enzyme 
immunoassay whose optical density index (GM-ODI) 
values are correlated with fungal burden and Aspergillus-
related disease progression [3]. Relevance of this test in 
IA diagnosis is criticized but remained the corner stone of 
decision tree in the management of fever in neutropenic 
patient, particularly during AML induction chemotherapy 
before prophylaxis area. This relevance is questionable 
since 2006 and the use of posaconazole as antifungal 
prophylaxis to prevent IFD during the neutropenic period 
following AML induction chemotherapy.
The current study aims to describe the breakthrough 
IA despite antifungal prophylaxis by posaconazole in 
a large cohort of AML patients during the induction 
chemotherapy. Moreover, this homogeneous population 
allowed us to determine the diagnostic accuracy of serum 
GM-ODI according to posaconazole plasma concentration 
in this specific context.
RESULTS
Characteristics of patients and treatments
Five hundred and eighty patients were initially 
identified for evaluation. We included 288 patients 
according to flow chart (Supplementary Figure 1) with 
a median follow-up about 13 months (range 1;75). 
Demographic and treatment characteristics of these 
patients are shown in Table 1. Briefly, median age was 
62 years, 4.1% of non-IA and 17.4% of IA patients had 
a history of chronic respiratory disease. All patients 
received standard dose of cytarabine, with daunorubicin 
for 35.1% or idarubicin for 64.6% of patients, 4.5% of 
patients received high dose cytarabine as second course 
of treatment for primary induction failure. Regimens 
of first and second induction courses are detailed in 
Supplementary Table 1. Median duration of neutropenia < 
1x109/L and < 0.5x109/L was respectively 24 and 21 days 
for non-IA patients and 31.5 and 29 days for IA patients. 
Deep neutropenia with absolute neutrophil count lower 
than 0.1x109/L for at least 1 day occurred in 38.9% of non-
IA patients and 47.8% of IA patients. Two-hundred thirty-
seven patients (83.8%) received granulocyte-colony-
stimulating-factor during induction.
Antifungal prophylaxis
All patients received posaconazole as prophylaxis 
treatment, with a median duration of treatment of 17 days 
(IQR 12.5-22, range 5;64). Posaconazole prophylaxis 
has been discontinued in 8 (2.8%) patients for adverse 
events including 6 liver toxicities and in 124 (43%) 
patients for empirical or curative antifungal treatment. 
Two hundred and fifty-eight patients had at least one 
posaconazole plasma dosage with a mean of 2.7 dosages 
by patient (range 1-9). We analyzed 701 posaconazole 
plasma concentrations. Considering the highest individual 
plasma concentration, median of posaconazole plasma 
concentration was 0.5 mg/L (IQR 0.3-0.8, range 0.1;2.4) 
for the whole cohort but 0.46 mg/L, 0.32 mg/L and 
0.18 mg/L in possible, probable and proven IA patients, 
respectively.
Characteristics and factors associated with IA
The overall incidence of possible, probable and 
proven IA was 8% (Table 2). Twelve patients had possible 
IA, characterized by clinical criteria without mycological 
or histological criteria. Among the 8 patients with probable 
IA, serum GM-ODI was ≥ 0.5 in 7 patients (87.5%) and 
GM-ODI in bronchoalveolar lavage (BAL) was ≥ 1 in 4 
patients among five patients tested. For the 3 patients with 
proven IA, the diagnosis of IA was made by lobectomy or 
bronchial biopsy. Among them, 2 had serum GM-ODI ≥ 
0.5 and 2 had GM-ODI ≥ 1 in BAL. Clinical, mycological 
and histological criteria used for EORTC/MSG 2008 sub 
group assignment are described in Table 2. Median delay 
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Table 1: Patients characteristics
Total Absence of IA-n (%) IA-n (%)
N=288 265 (92%) 23 (8%)
Age (years)
Median (IQR) 62 (50-67.5) 62 (51.5-68.5) 56 (49.5-68)
Range 17;83 17;83 22;73
Male gender-n (%) 165 (57.3) 149 (56.2) 16 (69.6)
Performance status-n (%)
0-1 219 (76) 204 (77) 15 (65.2)
≥ 2 59 (20.5) 51 (19.2) 8 (34.8)
Missing data 10 (3.5) 10 (3.8) 0
Comorbidities-n (%)
Chronic respiratory disease 15 (5.2) 11 (4.1) 4 (17.4)
Serum creatinine > 1.3 mg/dL 1 (0.3) 1 (0.4) 0
Cirrhosis 0 0 0
Diabetes mellitus 18 (6.3) 16 (6) 2 (8.7)
Host factor except neutropenia 0 0 0
WBC (G/L) at diagnosis
Median (IQR) 5 (2.1-33.1) 5 (2.1-32.2) 4.1 (2-50.6)
Range 0.3;269.2 0.3;269.2 0.4;134
ANC (G/L) at diagnosis
Median (IQR) 1.1 (0.4-3.7) 1.16 (0.4-3.7) 0.9 (0.5-3.2)
Range 0;81.6 0;81.6 0;12
FAB classification-n (%)
0-2 92 (31.9) 86 (32.5) 6 (26.1)
3 19 (6.6) 19 (7.2) 0
4-5 68 (23.6) 62 (23.4) 6 (26.1)
6-7 24 (8.4) 20 (7.5) 4 (17.4)
No FAB classification 85 (29.5) 78 (29.4) 7 (30.4)
WHO subtype-n (%)
De novo 230 (79.9) 213 (80.4) 17 (73.9)
Secondary 58 (20.1) 52 (19.6) 6 (26.1)
 MDS-related 14 (4.9) 12 (4.5) 2 (8.7)
 MPN-related 20 (6.9) 19 (7.2) 1 (4.3)
 tAML 24 (8.3) 21 (7.9) 3 (13)
Cytogenetics-n (%)
Favorable 49 (17) 46 (17.3) 3 (13)
Intermediate 180 (62.5) 166 (62.6) 14 (60.8)
Adverse 59 (20.5) 53 (20) 6 (26)
(Continued )
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from the beginning of chemotherapy to diagnosis of IA 
was 26 days (IQR 21-52, range 7;77). Median duration 
of absolute neutrophil count < 0.5x109/L was 25 days, 
36 days and 44 days for possible, probable and proven 
IA, respectively. Clinical presentations were poor, but 
fever was constant, with inconstant cough, chest pain or 
dyspnea. Half of the patients were still febrile after 72 
hours of antibacterial therapy and the other half became 
febrile after 48h of apyrexia under antibacterial therapy. 
Computerized tomography (CT) scans were performed 
one or two days after the onset of symptoms. The most 
frequent CT signs were nodules with or without halo, 
ground glass opacities and alveolar consolidation. In 
univariate analysis, factors significantly associated with 
these 23 possible, probable and proven IA are described in 
Table 3. In multivariate analysis, factors associated with 
IA were previous history of chronic respiratory disease 
(OR 5.79, 95%CI [1.51-22.24], p=0.0105) and duration of 
absolute neutrophil count < 0.5x109/L longer than 21 days 
(OR 4.34, 95%CI [1.39-13.57], p=0.0118) whereas patients 
with a posaconazole plasma concentration > 0.5 mg/L had 
a lower risk of IA (OR 0.22, 95%CI [0.07-0.67], p=0.0082) 
(Table 3). Treatments of IA are shown in Table 4. 
Twenty-two among the 23 IA patients received antifungal 
treatment with voriconazole whereas one exclusively 
received liposomal amphotericin B treatment. The 
3-month and one-year mortality rates were respectively 
18% and 73% for the probable and proven IA, versus 
5.3% and 18.1% in the non-IA population. Six patients 
died during the month following AML chemotherapy, two 
from a non-IA infection, 3 from AML progression, and 
one from cerebral hemorrhage.
Diagnostic accuracy of the serum GM assay
We then analyzed the diagnostic accuracy of 
serum GM assay for breakthrough IA in our population. 
Sensitivity and specificity of serum GM test were 
calculated considering the results of 2297 tests performed 
on samples obtained from 288 patients. Sensitivity was 
Total Absence of IA-n (%) IA-n (%)
N=288 265 (92%) 23 (8%)
Induction chemotherapy-n (%)
Daunorubicin-based 101 (35.1) 90 (34) 11 (47.8)
Idarubicin-based 186 (64.6) 175 (66) 11 (47.8)
Other 1 (0.3) 0 1 (4.4)
Reinduction chemotherapy-n (%)
High-dose cytarabine 13 (4.5) 8 (3) 5 (21.7)
Duration of ANC < 1x109/L (days)
Median (IQR) 24 (20.5-29.5) 24 (20.5-28.5) 31.5 (22-43)
Range 8;59 8;52 11;59
Duration of ANC < 0.5x109/L (days)
Median (IQR) 21 (18.5-27) 21 (17.5-27) 29 (23.5-40)
Range 3;51 3;49 10;51
ANC < 0.1x109/L
n (%) 117 (40.6) 103 (38.9) 11 (47.8)
Median duration (IQR) (days) 8.5 (3-14.5) 8 (3-14.5) 11 (7-23.5)
Range 1;29 1;29 2;24
Grade 4 mucositis-n (%) 28 (9.7) 23 (8.7) 5 (21.7)
Response to treatment-n (%)
CR-CRi after first induction course 223 (77.4) 220 (83) 16 (69.5)
CR-CRi after second induction course 4 (1.4) 4 (1.51) 0
IA: invasive Aspergillosis, WBC: white blood cell count, ANC: absolute neutrophil count, WHO: World Health 
Organization, MDS: myelodysplastic syndrome, MPN, myeloproliferative neoplasm, tAML: therapy-related acute myeloid 
leukemia, FAB: French-American-British classification, IQR: Interquartile range, CR: complete remission, CRi: complete 
response with incomplete blood recovery.
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Table 2: Invasive aspergillosis characteristics
Possible IA-n (%) Probable IA-n (%) Proven IA-n (%)
12 (4.2) 8 (2.8) 3 (1)
AML
Duration of ANC < 1x109/L
Median (IQR) 28 (22-34) 39 (32-48) 49 (21-55)
Range 11;47 22;59 21;55
Duration of ANC < 0.5x109/L
Median (IQR) 25 (21-30) 36 (28.5-41) 44 (21-51)
Range 10;40 21;48 21;51
AML treatment response-n (%)
CR-CRi 10 (83.3) 4 (50) 2 (66.7)
Primary or secondary induction 
failure 1 (8.3) 4 (50) 1 (33.3)
Death before evaluation 1 (8.3) 0 0
Prophylaxis
Posaconazole duration (days)
Median (IQR) 13 (9-26) 11 (8-17.5) 15 (7-20)
Range 5;64 5;41 7;20
Posaconazole plasma 
concentration (mg/L)a
Median (IQR) 0.46 (0.4-0.65) 0.32 (0.2-0.37) 0.18 (0.1-0.4)
Range 0.3;1 0.22;2.4 0.1;0.4
Clinical criteria
Clinical signs
Fever 12 (100) 8 (100) 3 (100)
Cough 3 (25) 2 (25) 1 (33.3)
Chest pain 3 (25) 0 0
Dyspnea/crackles 4 (33.3) 3 (37.5) 0
Chest CT signs
Nodule with halo sign 6 (50) 5 (62.5) 2 (66.7)
Nodule without halo 9 (75) 3 (37.5) 1 (33.3)
Cavity / Air crescent sign 0 0 0
Ground glass opacities 5 (41.7) 3 (37.5) 2 (66.7)
Alveolar consolidation 6 (50) 1 (12.5) 1 (33.3)
Centrilobular micronodules 3 (25) 2 (25) 0
Bronchoscopy
Performed/indicated-n 10/12 6/8 3/3
Normal 5 (50) 4 (66.7) 1 (33.3)
Inflammation 5 (50) 2 (33.3) 2 (66.7)
Tracheobronchitisb 1(10) 0 2 (66.7)
(Continued )
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defined by the proportion of patient with IA diagnosed 
by mycological criteria other than serum GM-ODI (i.e. 
positive culture or GM-ODI in BAL). Sensitivity of serum 
GM assay for the detection of probable and proven IA was 
81.8% 95%CI [48.2-97.7] and specificity was 96.4% 95%CI 
[93.5-98.3].
Ten patients were identified as false positives 
with a median follow-up about 31 months (range 2;62). 
Median age was 63.5 years, 40% of male gender, 80% 
has an ECOG < 2 at diagnosis, and one had an history of 
diabetes mellitus. Median duration of absolute neutrophil 
count < 1x109/L or < 0.5x109/L were both 22 days. Deep 
neutropenia with absolute neutrophil count lower than 
0.1x109/L for at least 1 day occurred in 50% of these ten 
patients. Median duration of posaconazole prophylaxis 
was 18 days (range 7;27) and median of posaconazole 
plasma concentration was 1 mg/L (range 0.3;1.31). Among 
these ten patients, two (20%) developed a fungemia (with 
Candida glabrata or Geotrichum capitatum) during the 
neutropenic period following the induction chemotherapy. 
We did not find well-known risk factors of false positive 
GM assay such as piperacillin-tazobactam, high-dose 
immunoglobulin or parenteral nutrition.
To describe the effect of posaconazole on diagnostic 
accuracy of serum GM assay to detect IA, we considered 
the highest posaconazole plasma concentration obtained 
by patient before possible, probable or proven IA 
diagnosis. Nine among the 124 patients (7.2%) with 
posaconazole concentration < 0.5 mg/L developed an 
IA: 6 were probable or proven with 5 serum GM positive 
test (ODI: 5.2, 0.54, 0.98, 1.56, 7.61) and 1 serum GM 
negative test (ODI: 0.37). Among the 134 patients 
with posaconazole plasma concentration ≥ 0.5 mg/L, 4 
developed an IA (2.9%) but none of them had a serum 
GM positive test. Taken together, these results suggest that 
the diagnostic accuracy of serum GM assay is impaired by 
high posaconazole concentration.
Variation of serum GM-ODI cut-off positivity
In view of this decreased diagnostic accuracy 
of the serum GM assay during effective posaconazole 
prophylaxis, we wondered whether decreasing the index 
cutoff value (ICV) could increase the sensitivity of serum 
GM test during posaconazole prophylaxis. Receiver 
operator characteristic curves analysis showed that serum 
GM assay accuracy was still effective to discriminate 
probable and proven IA (area under the curves =0.963). 
We showed an increase of sensitivity from 81.8%, 95%CI 
[48.2-97.7] to 90.9%, 95%CI [58.7-99.8] when ICV 
Possible IA-n (%) Probable IA-n (%) Proven IA-n (%)




> 0.5-n (%) 0 7 (87.5) 2 (66.7)
Mean (Range) 0.23 (0.11;0.46) 1.7 (0.23;5.2) 3.0 (0.37;7.6)
GM-ODI in BAL
Performed/bronchoscopy-n 8/10 5/6 2/3
GM-ODI > 1-n (%) 0 4 (80) 2 (100)
Mycological test in BAL
Performed/bronchoscopy-n 10/10 6/6 3/3
Positive direct examination 0 0 1 (33.3)
Positive culture 0 1 (16.6) 3 (100)




Examination of sterile material
Lobectomy or bronchial biopsy 0 0 IFD
IA: invasive Aspergillosis, AML: acute myeloid leukemia, IQR: Interquartile range, CR: complete remission, CRi: 
complete response with incomplete blood recovery, CT: computerized tomography, BAL: bronchoalveolar lavage fluid, 
GM-ODI: Galactomannan optical density index, IFD: invasive fungal disease, ANC: absolute neutrophil count.
a Highest posaconazole plasma concentration obtained by patient before diagnosis has been considered.
b Ulceration, nodule, pseudo membrane, eschar.
c Highest serum GM-ODI value obtained by patient before diagnosis of IA has been considered.
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decreased from 0.5 to 0.3 (Figure 1). With this new ICV, 
the serum GM test became positive for 4 additional 
patients who had serum GM negative test with a threshold 
at 0.5 (Supplementary Table 2). One patient had serum 
GM negative test but proven IA (case 4), 2 patients had 
clinical and chest-CT scan patterns highly suggestive of 
IA (case 1 and 3). Finally, the fourth patient (case 2) had a 
clinical evolution less in favor of IA, despite the isolation 
of an Aspergillus flavus in sputum sample and a serum 
GM-ODI at 0.43. Indeed, GM test specificity decreases 
from 96.4% with an ICV at 0.5 to 85.9% with an ICV at 
0.3.
DISCUSSION
Despite antifungal prophylaxis, IA remains a 
diagnostic and therapeutic challenge in AML patients 
[4–6]. In a randomized multicentric study, Cornely et 
al. demonstrated that posaconazole reduces incidence 
of IFD and prolongs overall survival of patients with 
prolonged neutropenia [7]. This study leads to Food 
and Drug Administration approval of posaconazole for 
the prophylaxis of IFD in patients who are at high risk 
of developing these infections. The decrease of serum 
GM test sensitivity by antifungal prophylaxis has been 
demonstrated by Marr et al. in 2005 in patients that 
received chemotherapy or allogenic hematopoietic stem 
cell transplant for various hematological malignancies, 
but posaconazole was not used in this work [8]. So, the 
current observational and retrospective study was focused 
on a homogeneous population of AML patients receiving 
induction chemotherapy with posaconazole prophylaxis, in 
order to analyze breakthrough IA and diagnostic accuracy 
of GM assay.
Incidence of IA in this studied population was 8%, 
with 3.8% of probable and proven IA. This incidence is 
higher than the one described in prospective randomized 
study by Cornely et al. [7], but consistent with the 
incidence in real-life studies previously reported in AML 
patients [4, 9–12]. We found exclusively pulmonary 
IA with poor clinical symptoms. Fever was the sole 
symptom in 20% of IA patients. Those limited clinical 
manifestations could possibly be explained by antifungal 
prophylaxis. This point has already been described by 
Peterson et al. who reported IA-related clinical symptoms 
in 31% and 4%, without and with antifungal prophylaxis, 
respectively [13]. We found that prolonged neutropenia 
and low posaconazole plasma concentration were factors 
associated with high risk of IA [14, 15], but also chronic 
respiratory comorbidity. In such a context, patients 
with chronic respiratory disease could be screened for 
Aspergillus colonization before chemotherapy.
Antifungal prophylaxis is known to reduce the 
fungal load in animal models [16, 17] and serum GM 
level is known to be correlated to this fungal load [3], 
particularly in neutropenic patients: posaconazole could 
reduce serum GM load and might impair diagnostic 
accuracy of the test. In the paper from Marr et al., 
specificity of serum GM test remained unchanged but 
the authors showed a sensitivity for detection of probable 
and proven IA in control arm and treatment arm about 
89% and 52%, respectively [8]. In the current study, all 
patients received antifungal prophylaxis by posaconazole 
oral suspension and sensitivity was 81.8% for a specificity 
about 96.4%. Moreover, we found that none patient with 
IA and posaconazole plasma concentration ≥ 0.5 mg/L 
had a serum GM positive test. We then tested a lower 
ICV and found an increased sensitivity of the serum GM 
test for probable and proven IA diagnosis. These results 
suggesting that posaconazole decreased the diagnostic 
accuracy of serum GM assay have been obtained in a 
specific population and should be taken with caution in 
other clinical situations. Indeed, the goal of an efficient 
prophylaxis is to lower the prevalence of a disease but 
the efficiency of a test is also highly dependent of this 
prevalence and spectrum of the disease [18, 19].
Table 3: Univariate and multivariate analyses of factors associated with possible, probable and proven IA under 
posaconazole prophylaxis
Univariate analysis Multivariate analysis
OR 95%CI p OR 95%CI p
Age (years) ≥ 62 0.59 0.24-1.40 0.232 - - -
Deep neutropenia (ANC < 0.1x109/L) 1.38 0.58-3.25 0.465 - - -
Chronic respiratory disease 4.86 1.26-15.81 0.024 5.79 1.51-22.24 0.0105
Grade IV mucositis 2.92 0.90-8.13 0.072 - - -
Posaconazole plasma concentration ≥ 0.5 mg/L a 0.22 0.06-0.60 0.002 0.22 0.07-0.67 0.0082
Duration of ANC < 0.5x109/L > 21 days 4.37 1.59-15.38 0.003 4.34 1.39-13.57 0.0118
a Highest posaconazole plasma concentration obtained by patient before diagnosis has been considered, ANC: absolute 
neutrophil count, OR: Odds ratio, CI: confidence interval.
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Table 4: Treatment and evolution of IA patients
Possible IA Probable and proven IA
n=12 n=11
Antifungal treatment-n a
Liposomal amphotericin B 6 3
Caspofungin 3 1
Voriconazole 11 10
Duration of treatment (days)-Mean (range)
Liposomal amphotericin B 7 (1;12) 8 (2;20)
Caspofungin 6 (3;9) 11 (3;25)
Voriconazole 100 (2;235) 130 (42;261)
Causes of Voriconazole discontinuation-n b
Complete response 10 5
Failure 0 1
Death 1 4
Clinical Response (days)-Mean (range)
Time to apyrexia 6 (1;14) 11 (1;19)
TDM evaluation-n 7 9
Aggravation 0 2
a Each patient can receive several treatments, b One patient with possible IA did not receive voriconazole, but only 
liposomal amphotericin B, IA: invasive aspergillosis.
Figure 1: Receiver operator characteristic curves, using multiple index cutoff values to define positivity. The index 
cutoff value defining positivity decreases from the highest to lowest value as the curve moves from left to right.
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This is a critical point since posaconazole is now 
available in tablet formulation that has been developed 
to optimize bioavailability. Cornely et al. indeed recently 
showed that with this tablet formulation, the average 
concentration was superior to 0.5 mg/L for 99% of 
the patients [20]. Another study recently described 
posaconazole levels in real-life patients: the mean of 
posaconazole plasma concentration was 1.32 mg/L versus 
0.81 mg/L, under tablet or oral suspension formulations, 
respectively [21].
Being aware of the drawbacks of our study 
design, we are convinced that our data make a valuable 
contribution in the field of IA risk management in AML 
patients during neutropenic period following induction 
chemotherapy. This study displays undoubtedly several 
bias due to its retrospective design and lack of systematic 
posaconazole plasma dosage (even if 90% had at least 
one dosage). We analyzed 2297 sera allowing strong 
multivariate analysis of risk factors associated with 
IA incidence. Whether these findings also translate 
into current practice with tablet formulation cannot 
be answered by our data but should be addressed by a 
prospective, multicentric study in the light of these results.
At our knowledge, posaconazole is not very prone 
to pharmacogenetic variability due to its low metabolism 
unlike voriconazole. If voriconazole is substrate and 
inhibitor of many isoforms of cytochrome P450, 
posaconazole is an inhibitor but only a weak substrate 
[22]. Actually, absorption is clearly the rate-limiting step 
for pharmacokinetics of posaconazole oral suspension. 
Other treatment interfere with results [23], particularly 
proton-pump inhibitors [24]. No data support interaction 
at distribution and elimination phases of pharmacokinetics 
and its metabolization is weak: the only drugs that could 
have an effect on these points are rifampicin and phenytoin 
that were not prescribed in these patients [25].
The last Infectious Diseases Society of America 
practice guidelines do not recommend anymore serum 
GM screening for asymptomatic patients receiving 
efficient mold-active antifungal prophylaxis [26]. The 
current study indeed suggests that AML patients with high 
posaconazole plasma concentration do not benefit from 
this screening policy. Such levels are mostly achieved with 
posaconazole tablet formulation, the galenic formulation 
currently used. Nevertheless, invasive aspergillosis 
remains a life-threatening infection that needs an early 
diagnosis. In our opinion, the IDSA recommendations 
should be taken with caution, only for patients with 
posaconazole plasma concentration ≥ 0.5 mg/L appended 
to a rigorous diagnostic-driven approach. The feasibility 
of this diagnostic-driven strategy has recently been 
assessed in a prospective study in high-risk hematology 
patients. The incidence of invasive fungal disease, fungal-
related death and all-cause mortality rates were similar in 
a classical approach and in a diagnostic-driven strategy. 
However, only hundred patients were included in the 
diagnostic-driven strategy arm, oral solution and not tablet 
formulation of posaconazole was used, and no data on 
posaconazole plasma concentration were submitted [27]. 
Finally, other diagnostic tools could support new screening 
strategies. Even if Aspergillus polymerase chain reaction 
is diminished under antifungal mold prophylaxis [28], its 
combination with serum GM assay have shown promising 
results [29, 30].
MATERIALS AND METHODS
Patients and prophylactic strategies
Selection criteria for this retrospective study were 
a diagnosis of AML according to WHO classification 
[31] between May 1st, 2008 and November 30, 2015 in 
the Department of Hematology and Cell Therapy of the 
Bordeaux University Hospital, > 17 years of age, without 
previous history of allogeneic or autologous hematopoietic 
stem cell transplant. Cytogenetic risk classification was 
defined according to the British Medical Research 
Council classification [32]. Patients have been included 
in the current study if they received at least 5 days of 
posaconazole prophylaxis (200 mg three times a day), 
exclusively by oral suspension. Posaconazole plasma 
concentration was monitored biweekly, started after 5 
days of treatment [33]. If concentration was lower than 0.7 
mg/L, posaconazole was increased to 200 mg four times a 
day. Written informed consents have been obtained from 
all patients in accordance with the Declaration of Helsinki, 
allowing the collection of clinical and biological data in 
an anonymized database, registered at the Commission 
Nationale Informatique et Libertés under N°1777604.
Laboratory diagnosis of IFD
Diagnostic procedures for the diagnosis of IFD 
routinely used galactomannan enzyme immunoassay in 
serum, bronchoalveolar lavage (BAL), and cerebrospinal 
fluid (CSF) besides histology, direct examination and 
culture on clinical specimens according to standard method 
[34]. Briefly, identification of fungi was done using 
classical phenotypically methods until implementation of 
matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS, Microflex, Bruker 
Daltonics): yeasts were identified using MALDI Biotyper 
V1.3 Software (Bruker Daltonics) since April 2013 and 
filamentous fungi were identified at the species level using 
an extended reference spectra library [35] since October 
2014. Mucormycosis diagnosis was carried out using 
PCR on serum in the Mycology Laboratory of Besancon 
University Hospital [36]. Serum GM tests were performed 
twice a week until neutropenia recovery, yielding a total 
of 2297 collected sera. Galactomannan detection was 
performed using the Platelia™ Aspergillus Ag kit (Bio-
Rad Laboratories, Marnes-la-Coquette, France) according 
Oncotarget26733www.oncotarget.com
to the manufacturer’s instructions. Serum, BAL and CSF 
were treated under a class 2 biological safety cabinet. 
Positive GM tests were controlled on the same sample 
and always verified on another sample. GM assay in BAL 
were performed in duplicate.
Monitoring of posaconazole plasma 
concentration
From December 1st, 2008 to February 15, 2010, the 
posaconazole plasma concentration was performed by high-
performance liquid chromatography (limit of detection/
LOD = 0.02 μg/mL and limit of quantification/LOQ = 0.05 
μg/ml) assay developed for a simultaneous determination of 
systemic azoles (fluconazole, posaconazole, voriconazole, 
itraconazole and its metabolite hydroxyl-itraconazole, and 
ketoconazole) as previously published [37]. Since February 
15, 2010, this posaconazole plasma concentration analysis 
is coupled with tandem mass spectrometry.
Diagnostic strategy and EORTC/MSG 2008 sub 
group assignment
AML patient’s characteristics are collected in 
an ongoing prospective database of the Department of 
Clinical Hematology and Cell Therapy. The clinical 
records of patients are evaluated to determine presence or 
absence of IA, date of diagnosis, date of clinical onset and 
receipt of antifungal therapies. Date of diagnosis was the 
earliest date among the day of suggestive computerized 
tomography (CT) scan or the day of microbiological or 
histopathological allowing diagnosis for probable and 
proven IA. The diagnosis of IFD was made in accordance 
with the revised EORTC/MSG definitions published 
in 2008 [2]. According to the above definitions, the 
whole cohort has host factor criteria with recent history 
of neutropenia (< 0.5x109 neutrophils/L for > 10 days). 
Diagnosis of possible IA was made according to clinical 
criteria of lower respiratory tract fungal disease on CT-
scan, trachea-bronchitis on bronchoscopic analysis, 
without mycological criteria. Diagnosis of probable IA 
was made from the documentation of one of the clinical 
or radiological findings described above associated with 
mycological criteria by isolation of mold in sputum, BAL 
or bronchial brush, or serum GM-ODI ICV > 0.5 or BAL 
GM-ODI ICV > 1. Diagnosis of proven IFD was retain 
by demonstrating fungus in diseased tissue (lobectomy or 
bronchial biopsy). All chest-CT scans have been routinely 
analyzed by a specialized radiologist (VL) and specifically 
reviewed for the study by an experienced pulmonary 
physician (EB) who was unaware of both clinical and 
biological results. CT images have been specifically 
examined in each lung and following radiological end 
points have been collected: nodule with or without halo 
sign, cavity / air crescent sign, ground glass opacities, 
alveolar consolidation, centrilobular micronodules, 
bronchiectases, pleural effusion, calcifications, and 
pneumothorax. Classical EORTC/MSG 2008 definitions 
were used for descriptive analysis of breakthrough IFD.
Statistical analysis
Diagnostic accuracy of serum GM-ODI was 
estimated by computing and presenting as sensitivity and 
specificity under the conditions of the serum GM-ODI 
ICV of 0.3, 0.4 and 0.5 with their 95% confidence interval 
(CI). We used standard methods for binomial proportions 
to calculate the CI. The receiver operating characteristic 
(ROC) curve was calculated and the area under the 
curves was reported. We estimated association between 
explanatory variables and IA (binary dependent variable) 
by performing a multivariable logistic regression. Variables 
and interaction terms associated (p < 0.20) with IA status 
were then included in a multivariate logistic regression 
model (p < 0.20). The analyses were performed using SAS 
9.3 (SAS institute Inc, Cary, NC) and R 3.2.2 [38].
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